Ogivri and Disease progression - a phase IV clinical study of FDA data

Summary:

Disease progression is reported as a side effect among people who take Ogivri (trastuzumab-dkst), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Docetaxel, and have Breast cancer.

The phase IV clinical study analyzes which people have Disease progression when taking Ogivri. It is created by eHealthMe based on reports of 196 people who have side effects when taking Ogivri from the FDA, and is updated regularly.

What is Ogivri?

Ogivri has active ingredients of trastuzumab-dkst. eHealthMe is studying from 197 Ogivri users. Check the latest studies of Ogivri.

What is Disease progression?

Disease progression is found to be associated with 1,800 drugs and 2,255 conditions by eHealthMe. Check the latest studies of Disease progression.

On Jul, 25, 2026

196 people reported to have side effects when taking Ogivri.
Among them, 15 people (7.65%) have Disease progression.

Among these 15 people:

How long have people been on Ogivri when they have Disease progression? *

What is the gender of people who have Disease progression when taking Ogivri? *

female: 69.23 %
male: 30.77 %

What is the age of people who have Disease progression when taking Ogivri? *

What are other drugs people take besides Ogivri? *

Docetaxel: 4 people, 26.67%
Paclitaxel: 1 person, 6.67%
Acetaminophen: 1 person, 6.67%

What are other side effects people have besides Disease progression? *

Death: 5 people, 33.33%
Lower Respiratory Tract Infection: 2 people, 13.33%
Pneumonia: 1 person, 6.67%
Nausea And Vomiting: 1 person, 6.67%
Nasopharyngitis (inflammation of the nasopharynx): 1 person, 6.67%
Metastatic Gastric Cancer (cancer types can spread to the stomach from other place): 1 person, 6.67%
Fever: 1 person, 6.67%
Endometrial Cancer: 1 person, 6.67%
Dyspnea (difficult or laboured breathing): 1 person, 6.67%
Diabetic Ketoacidosis (diabetic ketoacidosis (dka) is high concentrations of ketone bodies): 1 person, 6.67%

What are the existing conditions these people have? *

Breast Cancer: 5 people, 33.33%
Endometrial Cancer: 3 people, 20.00%
Breast Cancer Metastatic: 3 people, 20.00%
Metastatic Gastric Cancer (cancer types can spread to the stomach from other place): 2 people, 13.33%

* Approximation only. Some reports may have incomplete information.

Do you take Ogivri and have Disease progression?

- Check whether Disease progression is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ogivri:

Ogivri (197 reports)

Browse all side effects of Ogivri:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Disease progression:

Disease progression (1,800 drugs)

Browse all the conditions that are associated with Disease progression:

Disease progression (2,255 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on trastuzumab-dkst (the active ingredients of Ogivri) and Ogivri (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.